Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

BACKGROUND: Pucotenlimab, also called HX008, is a humanized anti-PD-1 antagonist IgG4 mAb. It blocks programmed cell death protein 1 (PD-1), programmed-death ligand 1 (PD-L1), and programmed death ligand-2 (PD-L2). In the CBCSG 006 trial, gemcitabine plus cisplatin (GP) has shown impressive antitumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jun, Wang, Biyun, Zhang, Jian, Tao, Zhonghua, Wang, Leiping, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379318/
https://www.ncbi.nlm.nih.gov/pubmed/35982961
http://dx.doi.org/10.3389/fonc.2022.837963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379318/
https://www.ncbi.nlm.nih.gov/pubmed/35982961
http://dx.doi.org/10.3389/fonc.2022.837963

Ejemplares similares